Liveramp Holdings Stock News

The acquisition of DataFleets significantly expands LiveRamp's (RAMP) privacy protection capabilities.

LiveRamp (RAMP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

RAMP, PLAB, MRVL, and VRS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 31, 2021.

DDI, FUNC, GDP, HFC, and RAMP have been added to the Zacks Rank #1 (Strong Buy) List on December 31, 2021.

LiveRamp (RAMP) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Technology services stocks CLBT, RAMP and RKT might witness a turnaround in 2022 and be solid investment options.

The mean of analysts' price targets for LiveRamp (RAMP) points to a 61.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst

Emerald Mutual Fund Advisers Trust reduced its stake in shares of LiveRamp Holdings, Inc. (NYSE:RAMP) by 13.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 423,635 shares of the companys stock after selling 68,484 shares during the quarter. []

OLD National Bancorp IN boosted its stake in shares of LiveRamp Holdings, Inc. (NYSE:RAMP) by 16.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 5,997 shares of the company’s stock after buying an additional 860 shares during the period. OLD National Bancorp IN’s holdings in LiveRamp were worth $283,000 at the end of the […]

LiveRamp Holdings, Inc. (NYSE:RAMP) has been assigned an average recommendation of Buy from the eleven analysts that are covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued []

An infection caused by a pandemic that attacks the liver and ends up in inflammation. viral hepatitis is treated with antiviral medication. In some individuals, newer medicines will eradicate the virus. Hepatitis C Drugs Market is expected to grow with CAGR

LiveRamp (NYSE:RAMP) was upgraded by Zacks Investment Research from a sell rating to a hold rating in a report issued on Wednesday, Zacks.com reports. According to Zacks, LiveRamp Holdings, Inc. operates as a marketing technology company. It provides data foundation, digital transformation, consumer engagement, and online marketing and analysis services. LiveRamp Holdings Inc., formerly known []

Royal Bank of Canada lessened its position in LiveRamp Holdings, Inc. (NYSE:RAMP) by 87.4% in the second quarter, HoldingsChannel.com reports. The fund owned 19,685 shares of the companys stock after selling 136,888 shares during the period. Royal Bank of Canadas holdings in LiveRamp were worth $923,000 as of its most recent filing with the Securities []

Zacks Investment Research upgraded shares of LiveRamp (NYSE:RAMP) from a sell rating to a hold rating in a research note published on Saturday, Zacks.com reports. According to Zacks, LiveRamp Holdings, Inc. operates as a marketing technology company. It provides data foundation, digital transformation, consumer engagement, and online marketing and analysis services. LiveRamp Holdings Inc., formerly []

LiveRamp Holdings, Inc. (NYSE:RAMP) has earned a consensus rating of Buy from the eleven research firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective []